Clinical Pathology Articles & Analysis
25 news found
During her time at the Charité Universitätsmedizin Berlin in Germany, Blum, MD, PhD played a central role in developing a GMP-compliant clinical platform for the use of TCR based cellular therapy in refractory AML, high-risk multiple myeloma and metastatic melanoma. In the context of complex government-sponsored initiatives she was able to coordinate activities of ...
ByArdigen
(“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the detection and clinical management of men >45 years of age at risk for prostate cancer. ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. The results of a recent clinical study performed at multiple sites within the US and Puerto Rico were presented at the 2022 American Urological Association's Annual Meeting. In the ...
In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize its AI-driven digital biomarker platform. ...
Publication of a large new study2 in the Journal of Clinical Pathology comparing the difference in turnaround time between in-house automated rapid PCR3 -based EGFR analysis and Next-Generation Sequencing (NGS) by an external laboratory, showing that 6% of the patients died before the NGS report was available. ...
Embedding this AI technology within PathPresenter’s emerging ClinPx platform – a scanner-agnostic digital pathology workflow solution – could accelerate the adoption of AI tools within clinical workflows. ...
MyOptiLab carries out complete analyses designed specifically for clinical pathology labs. It uses the Lean and Six Sigma methodologies applied widely in the industry and provides solutions for increasing productivity and improving patient quality of service. ...
“This publication shows for the first time that WATS3D helps to detect clinically-significant pathologic lesions and provides insight into the progression rates of BE and dysplasia to cancer,” said Bill Huffnagle, CEO of CDx Diagnostics. ...
Based on user analysis and evaluation of feedback from clinics, therapists and patients, we have further developed our system to relieve therapists. ...
Since lipidomics profiles are of great importance for studying developmental or pathological processes in tissue sections, MALDI-Imaging can serve as a useful tool for biomarker discovery. ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. ...
We were pleased to see not only slowing of cognitive and functional decline, but also very substantial clearance of amyloid plaques and slowing of spread of tau pathology. The constellation of clinical and biomarker results indicates the potential for long-term disease modification. ...
The company’s platform has significant potential for the development of novel therapies that mitigate underlying disease pathology, resulting symptoms, and disease progression in neurological diseases as well as oncology. ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. ...
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, January 5, 2021 at 8:00 PM EST. About Axial ...
This study highlighted the utility of the PARIS® Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS® Test: Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 8:40 AM EST. About ...
Axial R&D Leader to Chair Day-long Session on Clinical Trials for ASD and New Therapeutics Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that A. ...